Michelson Diagnostics

High-Level Overview

Michelson Diagnostics is a UK-based medical device company specializing in multi-beam Optical Coherence Tomography (OCT) technology for dermatology.[1][2][3] Its flagship product, the VivoSight OCT scanner (including models like VivoSight Dx and Dx Pro), is a point-of-care device that provides high-resolution, real-time cross-sectional images of skin tissue up to 1-1.5 mm deep, enabling clinicians to diagnose and monitor conditions like non-melanoma skin cancer (NMSC) without biopsies.[1][2][4][6] It serves dermatologists, researchers, and clinicians by solving the problem of inaccurate surface-based assessments, allowing earlier, more precise treatment decisions and reducing invasive procedures.[1][6]

The company generates revenue from VivoSight's commercial application in NMSC diagnosis, with ongoing advancements like upgraded software for lesion analysis and angiographic imaging to visualize morphologic changes.[1][6] Growth includes product launches (e.g., VivoSight Dx in 2015) and design enhancements for better user experience, positioning it as a leader in non-invasive skin imaging.[2]

Origin Story

Michelson Diagnostics was founded in March 2006 in Orpington, UK, by five physicists and engineers expert in laser scanning, initially to develop a hand-held cancer scanner using OCT technology.[3][5][6] In just four years, the team built, tested, and secured regulatory clearance for their system, demonstrating rapid progress from concept to market.[3] Early focus was on multi-beam OCT for dermatology, leading to the launch of the VivoSight scanner, with pivotal upgrades like new software in 2014 for skin lesion investigation and the VivoSight Dx at a 2015 dermatology congress.[1][2]

CEO Jon Holmes has emphasized providing cutting-edge tools for accurate skin condition diagnosis, building on collaborations with dermatologists to refine usability and patient experience.[1][2]

Core Differentiators

• Patented Multi-Beam OCT Technology: Delivers unprecedented high-definition resolution (<10 μm) and depth (>1 mm into dermis) using eye-safe infrared lasers, akin to optical ultrasound, for 3D sub-surface imaging not visible from skin surface.[1][2][6]
• Clinical Accuracy and Non-Invasiveness: Enables biopsy reduction by revealing lesion type, depth, and spread for NMSC and other conditions; upgraded features include angiographic visualization of blood flow changes.[1][6]
• User-Centric Design: Enhanced mobility, storage, and ergonomics via collaborations with dermatologists; models like Dx Pro are faster, easier to learn, and accessible for clinical, commercial, and research use.[2][6]
• Proven Regulatory and Market Path: FDA-cleared in four years; positioned as standard for non-invasive diagnosis of cutaneous conditions.[1][3]

Role in the Broader Tech Landscape

Michelson Diagnostics rides the trend toward non-invasive, real-time diagnostics in dermatology, fueled by rising NMSC incidence and demand for precision medicine.[1][4] OCT's timing aligns with advances in laser optics and AI-enhanced imaging, outpacing traditional biopsy methods amid growing tele-dermatology and point-of-care needs.[2][6] Market forces like aging populations and skin cancer prevalence favor its expansion, influencing the ecosystem by setting OCT as a dermatology standard and enabling research into epithelial diseases.[1][6]

Quick Take & Future Outlook

Michelson Diagnostics is poised to expand VivoSight's adoption with Dx Pro's angiographic capabilities, targeting broader clinical trials, academic research, and global dermatology markets.[6] Trends like integrated AI for automated analysis and portable OCT will shape its path, potentially evolving into multi-application platforms for other epithelial cancers. Its influence may grow by partnering with medtech firms, solidifying non-invasive imaging as dermatology's core tool and enhancing early detection outcomes.[1][6]